RAMM Pharma Corp. Announces Corporate Update

RAMM Pharma Corp. Announces Corporate Update
This section is Partnership Content supplied

The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.

by GlobeNewswire

Breadcrumb Trail Links

GlobeNewswire

Author of the article:

Published Mar 28, 2024  •  4 minute read

You can save this article by registering for free here. Or sign-in if you have an account.

Valeriana Officinalis L. (Valerian Root) GNW

Article content

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), is pleased to advise its shareholders that in accordance with its previously announced strategy of diversifying its product portfolio, in order to reduce its exposure to the strictly regulated environment of Cannabis-based products, it has launched the formulation and production of a full line of botanical-derived food supplements, through its subsidiary Hempoland Sp Zoo (“Hempoland”) under its Marishanti brand.

Advertisement 2

This advertisement has not loaded yet, but your article continues below.

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman, Victoria Wells and others. Daily content from Financial Times, the world’s leading global business publication. Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman, Victoria Wells and others. Daily content from Financial Times, the world’s leading global business publication. Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword.

REGISTER / SIGN IN TO UNLOCK MORE ARTICLES

Create an account or sign in to continue with your reading experience.

Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors.

Sign In or Create an Account

or

Article content

The Company expresses its recognition and thanks to the R&D, Quality and Production teams of Hempoland for their commitment and ongoing professional excellence.

Article content

Hempoland has successfully filed notification to the Competent Regulatory Authority for the first phase of its health supportive portfolio and has commenced sales in the EU with a view to international expansion including its online presence.

The product line available by April 30th, 2024, includes and will include:

 – Hypericum Perforatum   (“St. John’s Wort”)  – Valeriana Officinalis L.   (“Valerian Root”) –  Calendula Officinalis L.   (“Marigold Flower”) –  Salvia Officinalis L.   (“Sage Leaf”) –  Taraxacum Officinale F.H. Wigg   (“Dandelion Root”) –  Crataegus spp   (“Hawthorn”) –  Melissa Officinalis L.   (“Melissa Leaf”) –  Ribes Nigrum L.   (“Blackcurrant”)        

The beneficial properties of the above have been extensively tested and documented in numerous academic reviews and research papers.

Additional SKUs, including non-restrictive functional mushroom, are under current development and Management expects to commence sales in 3Q2024.

Top Stories

Thanks for signing up!

Article content

Advertisement 3

This advertisement has not loaded yet, but your article continues below.

Article content

The use of plant extracts is experiencing strong growth in the global market as consumers seek out natural and healthy products with beneficial properties. The urban population, with evolving lifestyles, has become increasingly health-conscious resulting in wider acceptance of alternative natural products fuelling the growth of botanical-derived food supplements. The global plant-extract market was estimated at USD 34.4 billion in 2022 and it is projected to grow at a CAGR of 12.3% to reach USD 61.5 billion by 2027 (source: www.marketsandmarkets.com).

About RAMM Pharma Corp.RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis- based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant -derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp- based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company’s state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay and Elblag, Poland.

Advertisement 4

This advertisement has not loaded yet, but your article continues below.

Article content

In Europe, RAMM’s vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include large extraction and processing facilities. RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland S.p.a. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.wearerammpharma.com.

For further information, please contact:

José Roldan Interim CFO+598 2513 99 58info@rammpharma.com

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forwardlooking statements“) within the meaning of the applicable Canadian securities legislation. All statements, other thanstatements ofhistoricalfact,areforward-lookingstatementsandarebasedonexpectations,estimatesandprojectionsas at the date of this news release. Any statement that involves discussions with respect to predictions, expectations,beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrasessuch as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”, “plans”, “budget”,“scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating thatcertain actions, events or results “may” or “could”, “would”, “might” or “wi ll” be taken to occur or be achieved) are notstatements of historical fact and may be forward-looking statements. In this news release, forward looking statementsrelate,amongotherthings,the Company’sstrategiesandobjectives,andfuture expansionplans.

Advertisement 5

This advertisement has not loaded yet, but your article continues below.

Article content

These forward-looking statements are based on reasonable assumptions and estimatesof management of theCompany at the time such statements were made. Actual future results may differ materially as forward -lookingstatements involve known and unknown risks, uncertainties and other factors which may cause the actual results,performanceorachievementsoftheCompanytomateriallydifferfromanyfutureresults,performanceorachievementsexpressed or implied by such forward-looking statements. Such factors, among other things, include: future growthpotential of theCompany; fluctuations ingeneralmacroeconomic conditions; fluctuations insecuritiesmarkets;expectationsregardingthesizeoftheUruguayan,LatinAmerican,Europeanandinternationalmedicalandrecreationalcannabis markets and changing consumer habits; the ability of the Company to successfully achieve its businessobjectives; plans for expansion; political and social uncertainties; inability to obtain adequate insu rance to cover risksand hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production,distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations.Although the forward-looking statements contained in this news release are based upon what management of theCompany believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholdersthat actual results will be consistent with such forward -looking statements, as there may be other factors that causeresultsnottobeasanticipated,estimatedorintended.Readersshouldnotplaceunduerelianceontheforward-lookingstatementsandinformationcontainedinthisnewsrelease.TheCompanyassumesnoobligationtoupdatetheforward-lookingstatementsofbeliefs,opinions,projections,orotherfactors,shouldtheychange,exceptasrequiredbylaw.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the informationcontainedherein.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fab821be-3712-40a7-a7d8-da7ecb69b28b

Article content

Share this article in your social network

The post RAMM Pharma Corp. Announces Corporate Update first appeared on Investorempires.com.

 

3 hot new ideas to start your week 🔥 | Raging Bull

Read More |    Accelerator Starts TOMORROW! Your chance to learn all our TOP options selling strategies in a small-group environment starts Monday!  All sessions recorded for on-demand learning – no excuses! Contact Davis for more info: 1-800-585-4488 / [email protected] Hey Folks, Jeff Bishop here. I’m having a fun weekend with my son’s college buddies, […]

Funds In The Shadows: ISIS Expands Crypto Usage For Fundraising And Money Laundering, Report | Investorempires.com

Read More | A recent Bloomberg report revealed that the Islamic State (IS) is allegedly growing its use of cryptocurrencies, including Tether’s USDT stablecoin, to raise and transfer funds globally, with a particular focus on Africa. The Counter ISIS Finance Group, a coalition of nations dedicated to combating the militant group’s financing, revealed these findings.  […]